MENU
+Compare
RNA
Stock ticker: NASDAQ
AS OF
Sep 12 closing price
Price
$44.74
Change
+$3.70 (+9.02%)
Capitalization
5.76B

RNA Avidity Biosciences Forecast, Technical & Fundamental Analysis

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs... Show more

RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RNA with price predictions
Sep 12, 2025

Momentum Indicator for RNA turns negative, indicating new downward trend

RNA saw its Momentum Indicator move below the 0 level on September 10, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In of the 94 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RNA moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for RNA turned negative on August 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where RNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 50-day moving average for RNA moved above the 200-day moving average on August 11, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .

RNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 215 cases where RNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.826) is normal, around the industry mean (20.524). P/E Ratio (0.000) is within average values for comparable stocks, (53.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.172). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (337.274).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RNA is expected to report earnings to fall 7.44% to -112 cents per share on November 11

Avidity Biosciences RNA Stock Earnings Reports
Q3'25
Est.
$-1.12
Q2'25
Missed
by $0.25
Q1'25
Missed
by $0.02
Q4'24
Est.
$-0.80
Q3'24
Beat
by $0.06
The last earnings report on August 07 showed earnings per share of -121 cents, missing the estimate of -95 cents. With 12.96M shares outstanding, the current market capitalization sits at 5.76B.
A.I. Advisor
published General Information

General Information

a company which engages in the research and development of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10578 Science Center Drive
Phone
+1 858 401-7900
Employees
253
Web
https://www.aviditybiosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNWBX89.160.16
+0.18%
American Funds New World R2
GCBLX36.60N/A
N/A
Green Century Balanced
RNTTX50.72N/A
N/A
Russell Inv International Devd Mkts M
FOCSX19.07N/A
N/A
Fidelity Small Cap Growth K6
AMAEX10.54N/A
N/A
American Century Small Cap Dividend Inv

RNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+9.02%
DYN - RNA
59%
Loosely correlated
-0.19%
ACLX - RNA
55%
Loosely correlated
-1.92%
OCUL - RNA
52%
Loosely correlated
+0.31%
CRNX - RNA
50%
Loosely correlated
+0.80%
ROIV - RNA
48%
Loosely correlated
-2.29%
More